Karyopharm (KPTI) news
Recent news
Karyopharm extends forbearance period to Oct. 22
AInvest Wire · 18h agoKaryopharm: Sees cash runway into Oct.15
AInvest Wire · Sep 11, 2026Karyopharm Therapeutics - To pay fees in shares of newly created preferred stock - SEC filing
Karyopharm Therapeutics has announced plans to pay fees using shares of newly created preferred stock, as disclosed in a recent SEC filing. This move aligns with the company's ongoing efforts to manage its capital structure and reduce cash outflows. The filing details the issuance of preferred…
AInvest Wire · Sep 11, 2026Karyopharm: Added time to continue myelofibrosis program
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has continued its clinical development program for myelofibrosis, with additional time allocated to evaluate long-term outcomes from its Phase 3 SENTRY trial. The trial, which evaluated the combination of selinexor and ruxolitinib in JAK inhibitor-naïve…
AInvest Wire · Sep 11, 2026Karyopharm Therapeutics - Did not pay $15.80 mln principal installment due Sept 10, 2026 - SEC filing
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) did not pay a $15.80 million principal installment that was due on September 10, 2026, according to a recent SEC filing. This non-payment is highlighted in the company’s latest 8-K report, which details ongoing liquidity challenges and failure to meet…
AInvest Wire · Sep 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.